Efficacy of Whole-Body Vibration Training on Brain-Derived Neurotrophic Factor, Clinical and Functional Outcomes, and Quality of Life in Women with Fibromyalgia Syndrome: A Randomized Controlled Trial.

Vanessa Gonçalves César Ribeiro ,Rosalina Tossige-Gomes,Borja Sañudo,Ana Caroline Negreiros Prates ,Luana Aparecida Soares ,Vanessa Pereira De Lima ,Henrique Silveira Costa ,Ana Cristina Rodrigues Lacerda ,Renato Fleury Cardoso ,J Flor ,Ana Oliveira ,Alessandra De Carvalho Bastone ,Vanessa Amaral Mendonça ,Sueli Ferreira Da Fonseca ,Pedro Henrique Scheidt Figueiredo ,Jousielle Márcia Dos Santos ,José Luiz Fernandes ,Alessandro Sartório ,Arthur Nascimento Arrieiro ,Bruna Caroline Chaves Garcia ,Danúbia Da Cunha De Sá-Caputo ,Mário Bernardo-Filho ,Hércules Ribeiro Leite ,Redha Taı̈ar

doi:10.1155/2021/7593802

Abstract

This study aimed to investigate the efficacy of whole-body vibration training (WBVT) on blood brain-derived neurotrophic factor (BDNF) levels and determine the clinical and functional outcomes in patients with fibromyalgia syndrome (FMS). Thirty-two women with FMS were randomized into an intervention group (IG), receiving 6 weeks of WBVT, or a control group (CG) with no intervention. The outcomes at the baseline and follow-up in both groups included blood BDNF levels, sit-to-stand test (STS), 6-minute walk test (6MWT), Fibromyalgia Impact Questionnaire (FIQ), Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and visual analogue scale (VAS). WBVT resulted in a group-by-time interaction effect. Thus, after the intervention time, the IG had increased blood BDNF levels (p=0.045), a higher number of repetitions on the STS test (p=0.011), and increased walking distance on the 6MWT (p=0.010), compared to CG. Moreover, there was a reduction in the scores of the FIQ (p=0.001), the PSQI (p=0.001), the BDI (p=0.017), and pain assessed using VAS (p=0.008) in IG. The results demonstrate that WBVT promotes an increase in blood BDNF levels, with concomitant improvement in lower limb muscle strength, aerobic capacity, clinical symptoms, and quality of life in women with FMS. This trial is registered with Brazilian Clinical Trials Registry (REBEC; RBR-38nbbx) (https://ensaiosclinicos.gov.br/rg/RBR-38nbbx).

Highlights

Fibromyalgia syndrome (FMS) is characterized by chronic widespread pain, neuroinflammation [1], nociception-driven amplification of neural signalling [2], systemic low-grade inflammation, and muscle dysfunction [3–5]. ese central and peripheral changes often occur concomitantly with clinical symptoms, such as depression [6] and sleep disturbance [7], which may compromise the biological rhythms
Once some interventions like exercise enhance the expression of Brain-derived neurotrophic factor (BDNF) in normal and pathological conditions, it is crucial to evaluate the efficacy of complementary therapeutic interventions on BDNF levels in FMS
36 did not meet the inclusion criteria and 3 refused to participate. us, 32 women with FMS participated in the study and were randomized into two groups, that is, 17 patients in the intervention group (IG) and 15 in the control group (CG) (Figure 1)

Summary

Introduction

Fibromyalgia syndrome (FMS) is characterized by chronic widespread pain, neuroinflammation [1], nociception-driven amplification of neural signalling (central sensitization) [2], systemic low-grade inflammation, and muscle dysfunction [3–5]. ese central and peripheral changes often occur concomitantly with clinical symptoms, such as depression [6] and sleep disturbance [7], which may compromise the biological rhythms. Fibromyalgia syndrome (FMS) is characterized by chronic widespread pain, neuroinflammation [1], nociception-driven amplification of neural signalling (central sensitization) [2], systemic low-grade inflammation, and muscle dysfunction [3–5]. It may lead to a decrease in physical function, modifying the quality of life [3]. Brain-derived neurotrophic factor (BDNF) is a key molecule involved in plastic changes related to central and peripheral plasticity, neuroinflammation, pain, and other clinical symptoms in pathological conditions including FMS [1, 8]. FMS has a vastly negative impact on clinical and functional aspects, and current literature points to physical exercise and cognitive-behavioral therapy as the nonpharmacological choice interventions [9]. Evidence-supporting therapies for the management of FMS are limited to small trials of low methodological quality [10]. Mascarenhas et al, in a recent review, found moderate-quality evidence of a positive association between pain-reduction exercises and improved quality of life. e authors suggested that further highquality trials might increase certainty with respect to the effectiveness of exercises in FMS [10]

Methods

Results

Conclusion